Pembrolizumab,Axitinib,Sunitinib
Merck,Pfizer
['key,note,42', 'pembro', 'rcc,(-irccs),(-srcc),(-urcc)', 'keynote-426', 'key,note,426']
5-year keynote-426 update: pembro + axi vs sun 1l rx for adv ccrcc #asco23 pembro + axi vs sun: pfs: hr 0.69, 95% ci 0.59-0.81 os: hr 0.84, 95% ci 0.71-0.99 orr: 60.6% vs 39.6% mdor: 23.6 vs 15.3 mo imdc int/poor risk - os: hr 0.76, 95% ci 
Uro Onc @GACancerCenter | Assoc Prof, Resident PD, and Ronald W. Lewis, MD Chair of Uro Educ @mcg_urology | #mentalhealth research | @urotoday Contributor